CNMD
NYSECONMED CORPORATION
Technology · Electromedical & Electrotherapeutic Apparatus
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$1.0B
2021
$1.0B
2022
$1.2B
2023
$1.3B
2024
$1.4B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$1.4B
Net Income$47.1M
Gross Profit$750.5M
Oper Income$102.6M
EPS (dil)$1.51
Rev/sh$44.59
FCF/sh$4.89
Book/sh$33.51
Gross M54.6%
Oper M7.5%
Profit M3.4%
FCF M11.0%
ROE4.6%
ROA2.0%
ROIC3.8%
R&D/Rev4.1%
Rev Y/Y5.2%
Rev 3Y CAGR9.6%
EPS Y/Y-64.5%
EPS 3Y CAGR—
FCF 3Y CAGR135.3%
Payout53%
Div/sh$0.60
Shs Chg Y/Y0%
Current Ratio2.14
Quick Ratio1.01
Debt/Eq0.78
Int Coverage3.3×
Net Debt$766.8M
Total Debt$807.7M
Cash & Eq$40.8M
Total Assets$2.3B
Oper CF$170.7M
Capex$19.8M
Free CF$150.9M
Buybacks$0
Equity$1.0B
Liabilities$1.3B
Shs Outstand0.03B
SectorTechnology
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.0B | $1.0B | $1.2B | $1.3B | $1.4B |
| Gross Profit | $568.0M | $571.2M | $676.2M | $733.0M | $750.5M |
| Operating Income | $109.7M | $70.1M | $120.6M | $200.3M | $102.6M |
| Net Income | $62.5M | $-80.6M | $64.5M | $132.4M | $47.1M |
| Diluted EPS | $1.94 | $-2.68 | $2.04 | $4.25 | $1.51 |
| Operating Cash Flow | $111.8M | $33.4M | $125.3M | $167.0M | $170.7M |
| Free Cash Flow | $96.9M | $11.6M | $106.3M | $153.9M | $150.9M |
COMMUNITY · $CNMD0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.